Move Over PDL1: New Test Combo Adds RNAseq to Better Track Immune Escape

Mendelspod Podcast

Content provided by Mendelspod Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mendelspod Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

7y ago

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on August 29, 2022 10:12 (1+ y ago). Last successful fetch was on July 07, 2022 16:01 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Reports from ASCO, the nation’s biggest cancer conference, this year again were full of stunning stories about the success of older and new immuno therapies. The race has never been hotter for biomarkers to target patient groups. Most of this new class of drugs--which harnesses the immune system to go after the cancer--inhibit an immune checkpoint called programmed cell death protein 1 or PDL1. So frontline cancer treatment these days typically includes a test for the PDL1 biomarker.

398 episodes

#Genetic Testing #Biology #Science #Natural Sciences